Patient-Reported Outcomes of Quality of Life, Functioning, and Depressive Symptom Severity in Major Depressive Disorder Comorbid With Panic Disorder Before and After Ssri Treatment in the Star*d Trial

Abstract

Background Panic disorder (PD) is highly comorbid with major depressive disorder (MDD) with potential impact on patient-reported outcomes of quality of life (QOL), functioning, and depressive symptom severity Methods Using data from the sequenced treatment alternatives to relieve depression (STAR*D) trial, we compared entry and post-SSRI-treatment QOL, functioning, and depressive symptom severity scores in MDD patients with comorbid PD (MDD+PD) to MDD patients without PD (MDDnoPD). We also compared pre- and posttreatment proportions of patients with severe impairments in quality of life and functioning. Results MDD+PD patients experienced significantly lower QOL and functioning and more severe depressive symptoms than MDDnoPD patients at entry. Following treatment with citalopram, both groups showed significant improvements, however, nearly 30–60% of patients still suffered from severe quality of life and functioning impairments. MDD+PD patients exited with lower QOL and functioning than MDDnoPD patients, a difference that became statistically insignificant after adjusting for baseline measures of depressive symptom severity, functioning, and QOL, comorbid anxiety disorders (PTSD, GAD, social, and specific phobias), age, and college education. Conclusions Functional outcomes using QOL and functioning measures should be utilized in treating and researching MDD so that shortfalls in traditional treatment can be identified and additional interventions can be designed to address severe baseline QOL and functioning deficits in MDD comorbid with PD.

Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder

“…Compared to Western studies involving MDD patients10193233, the 71.7% prevalence of comorbid GAD that we found in this study was higher. Our prevalence estimate was also higher than the one reported in a Chinese study by Gao et al 34,.…”

Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment‐seekers with cannabis use disorder

“…For individuals who were abstinent, their QLES‐Q‐SF scores were higher by 6.78 points (12%), correlating with greater than one standard deviation of improvement as seen in community samples (SD = 11.3%). This is a clinically meaningful improvement as supported by previous studies examining changes in QLES‐Q‐SF during treatment for major depressive disorder . Individuals with CUD, by definition, are having impairment across many areas of their life as a result of their cannabis use.…”

Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study

“…Correlating reduction in opioid use with changes in functioning can help guide an overall treatment strategy. Indeed, research in depression and anxiety disorders 52 has shown that quality of life assessments can add an important dimension to overall evaluation of patients’ treatment response, as symptom measures do not always present a complete picture of a patient’s overall functioning or recovery. Furthermore, brief, widely-used measures of health-related quality of life such as the SF-36 enable comparisons of these factors between different patient populations that can inform both clinical treatment selection and policy decisions about the allocation of health care resources.…”